AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6753893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of captopril and hydrochlorothiazide
Number of subjects: 207
Study 6753893 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 207
Study 31904682 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 5407
Study 31904682 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 5407
Study 30093398 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib therapy
Number of subjects: 2712
Study 28378369 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4053
Number of subjects: 200
Study 28378369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 200
Study 28378369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26096461 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitai tablets
Number of subjects: 64
Study 26096461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 26096461 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitai tablets and Placebo
Number of subjects: 64
Study 24259652 — intervention group
Group type: EXPERIMENTAL
Intervention: LWD + CMM (Living Well With a Disability + Collaborative Medication Management)
Number of subjects: 0
Study 24259652 — intervention group
Group type: COMPARATOR
Intervention: LWD only
Number of subjects: 0
Study 24259652 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21843832 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive static stretching regimen
Number of subjects: 22
Study 21843832 — intervention group
Group type: COMPARATOR
Intervention: Mock passive stretching regimen
Number of subjects: 22
Study 19006657 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation
Number of subjects: 36
Study 17720383 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 30
Study 17720383 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 30
Study 17720383 — intervention group
Group type: COMPARATOR
Intervention: CABG and OPCAB
Number of subjects: 30
Study 15108078 — intervention group
Group type: EXPERIMENTAL
Intervention: Exxcel grafts
Number of subjects: 94
Study 15108078 — intervention group
Group type: COMPARATOR
Intervention: Gore-tex grafts
Number of subjects: 94
Study 11236936 — intervention group
Group type: EXPERIMENTAL
Intervention: L10M regimen
Number of subjects: 195
Study 11236936 — intervention group
Group type: COMPARATOR
Intervention: DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating methotrexate (MTX) and L-asparaginase (L-asp)
Number of subjects: 195
Study 11236936 — intervention group
Group type: COMPARATOR
Intervention: DAT/MTX/L-asp regimen
Number of subjects: 195
Study 9633704 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment (1,000 mg IV infusion followed by 200 mg/day subcutaneously for 16 weeks)
Number of subjects: 45
Study 9633704 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment
Number of subjects: 45
Study 7541258 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide 0.2 mg
Number of subjects: 60
Study 7541258 — intervention group
Group type: EXPERIMENTAL
Intervention: octreotide 0.1 mg
Number of subjects: 60
Study 7541258 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 3291150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol therapy starting with 40 mg and increasing to 120 mg, followed by the maximal dose tolerated every 6 hours for 72 hours
Number of subjects: 30
Study 3291150 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 30343858 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (20 mg methylprednisolone acetate)
Number of subjects: 234
Study 30343858 — intervention group
Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 234
Study 28156011 — intervention group
Group type: COMPARATOR
Intervention: Single doses of LY2979165 (20-150 mg)
Number of subjects: 114
Study 28156011 — intervention group
Group type: COMPARATOR
Intervention: Multiple once-daily doses of LY2979165 (20-400 mg)
Number of subjects: 114
Study 25681277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 25681277 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 50 mg bid
Number of subjects: 87
Study 25681277 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5069 80 mg bid
Number of subjects: 87
Study 23441793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanotite (N) implants
Number of subjects: 7
Study 23441793 — intervention group
Group type: COMPARATOR
Intervention: Osseotite (O) implants
Number of subjects: 7
Study 21713440 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol (Xenetix® 300)
Number of subjects: 146
Study 21713440 — intervention group
Group type: COMPARATOR
Intervention: iodixanol (Visipaque® 270)
Number of subjects: 146
Study 18312423 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injection
Number of subjects: 35
Study 18312423 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessments
Number of subjects: 35
Study 16569171 — intervention group
Group type: EXPERIMENTAL
Intervention: General questioning
Number of subjects: 83
Study 16569171 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific questioning
Number of subjects: 83
Study 16569171 — intervention group
Group type: COMPARATOR
Intervention: Repeated questioning (interview at 3 months)
Number of subjects: 83
Study 16569171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior knowledge assessment
Number of subjects: 83
Study 12502473 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 45
Study 12502473 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study 10784627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone, etoposide, and cyclosporine (MEC) therapy: mitoxantrone 6 mg/m2/d for 5 days, etoposide 60 mg/m2/d for 5 days, and CSA 10 mg/kg for 2 hours followed by 30 mg/kg/d as a continuous infusion for 98 hours.
Number of subjects: 66
Study 10784627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) levels greater than 2,400 ng/mL.
Number of subjects: 66
Study 10784627 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicities associated with MEC therapy.
Number of subjects: 66
Study 10784627 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 status evaluation.
Number of subjects: 66
Study 8895285 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G 125 micrograms
Number of subjects: 75
Study 8895285 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G 100 micrograms
Number of subjects: 75
Study 8895285 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate 500 micrograms
Number of subjects: 75
Study 1512659 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL acuity testing
Number of subjects: 42
Study 1512659 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL acuity
Number of subjects: 42
Study 1512659 — intervention group
Group type: EXPERIMENTAL
Intervention: VEP acuity
Number of subjects: 42
Study 1512659 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuity difference score (FPL minus VEP)
Number of subjects: 42
Study 1512659 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scores of visual behaviors
Number of subjects: 42
Study 6386512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline, 7.5 mg 2 times/day
Number of subjects: 25
Study 6386512 — intervention group
Group type: COMPARATOR
Intervention: Ordinary salbutamol tablets, 4 mg 3 times/day
Number of subjects: 25
Study 31180829 — intervention group
Group type: EXPERIMENTAL
Intervention: nBETTER therapy (EEG-based MI-BCI with visual feedback)
Number of subjects: 13
Study 31180829 — intervention group
Group type: COMPARATOR
Intervention: BCI with haptic knob (BCI-HK)
Number of subjects: 13
Study 31180829 — intervention group
Group type: COMPARATOR
Intervention: Standard arm therapy (SAT)
Number of subjects: 13
Study 29335328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 000 steps per day prescription for 10 weeks
Number of subjects: 46
Study 29335328 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal activity habits)
Number of subjects: 46
Study 27430612 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101
Number of subjects: 258
Study 27430612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 25154607 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil (100 mg daily for three months)
Number of subjects: 80
Study 25154607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23713743 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 3 ng/mL
Number of subjects: 10
Study 23713743 — intervention group
Group type: COMPARATOR
Intervention: Methylnaltrexone 0.15 mg/kg
Number of subjects: 10
Study 23713743 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 19924497 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty (BKP)
Number of subjects: 0
Study 19924497 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study 18768020 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered filament toothbrush (TFTB)
Number of subjects: 32
Study 18768020 — intervention group
Group type: COMPARATOR
Intervention: Control toothbrush (ADA)
Number of subjects: 32
Study 16819358 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tissue Tonometer (MTT)
Number of subjects: 24
Study 16583964 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia + epidural anesthesia combined group
Number of subjects: 50
Study 16583964 — intervention group
Group type: COMPARATOR
Intervention: Control group (only general anesthesia)
Number of subjects: 50
Study 10815350 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) interventions
Number of subjects: 258
Study 10815350 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 258
Study 9193380 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg/day)
Number of subjects: 1862
Study 9193380 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg/day)
Number of subjects: 1862
Study 9193380 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol and beta-carotene (50 mg/day and 20 mg/day respectively)
Number of subjects: 1862
Study 9193380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1862
Study 8194434 — intervention group
Group type: COMPARATOR
Intervention: daily‐aspirin‐treated group (aspirin, 300mg, once everyday)
Number of subjects: 42
Study 8194434 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent‐aspirin‐treated group (aspirin, 300mg, once every three days)
Number of subjects: 42
Study 8194434 — intervention group
Group type: COMPARATOR
Intervention: non‐aspirin‐treated group
Number of subjects: 42
Study 8194434 — intervention group
Group type: COMPARATOR
Intervention: normal subjects group
Number of subjects: 42
Study 3517243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (100 mg/m2)
Number of subjects: 91
Study 3517243 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cisplatin (20 mg/m2) and chlorambucil
Number of subjects: 91
Study 29708829 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1000 mg i.m. every 10 weeks)
Number of subjects: 55
Study 29708829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 27682295 — intervention group
Group type: EXPERIMENTAL
Intervention: InterTAN nail (ITN)
Number of subjects: 78
Study 27682295 — intervention group
Group type: COMPARATOR
Intervention: third generation gamma nail (GN)
Number of subjects: 78
Study 24530176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target systolic blood pressure <140 mm Hg within 1 h using locally available intravenous drugs)
Number of subjects: 2839
Study 24530176 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment (target systolic blood pressure <180 mm Hg within 6 h of onset of ICH)
Number of subjects: 2839
Study 24530176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 2839
Study 24530176 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment
Number of subjects: 2839
Study 22931483 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-commercial music for 45 minutes at nocturnal sleep time
Number of subjects: 28
Study 22931483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 28
Study 20591807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES)
Number of subjects: 36
Study 20591807 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 18412023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin 500 mg capsules
Number of subjects: 0
Study 18412023 — intervention group
Group type: COMPARATOR
Intervention: Reference product (not specified)
Number of subjects: 0
Study 16618841 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (8.8+/‐1.4 ng/kg)
Number of subjects: 6
Study 16618841 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (2.0+/‐0.3 microg/kg)
Number of subjects: 6
Study 16618841 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (52+/‐12 ng/kg)
Number of subjects: 6
Study 12590029 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg daily plus morphine
Number of subjects: 0
Study 12590029 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 80 mg daily plus morphine
Number of subjects: 0
Study 12590029 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus morphine
Number of subjects: 0
Study 10954937 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatology-trained practice nurse intervention
Number of subjects: 109
Study 10954937 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 109
Study 8614421 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for cervical chlamydial infection
Number of subjects: 2607
Study 8614421 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2607
Study 1283088 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (two cycles of cisplatin, bleomycin, vindesine, mitomycin C)
Number of subjects: 208
Study 1283088 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (three cycles of cisplatin, 5-fluorouracil continuous infusion, and vindesine)
Number of subjects: 208
Study 1283088 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (both regimens)
Number of subjects: 208
Study 3884019 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dimethyl sulfoxide (DMSO)
Number of subjects: 84
Study 3884019 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% dimethyl sulfoxide (DMSO)
Number of subjects: 84
Study 3884019 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.85% normal saline
Number of subjects: 84
Study 30815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application (MPA) only (Group C)
Number of subjects: 185
Study 30815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MPA and self-monitoring of blood glucose (SMBG) (Group D)
Number of subjects: 185
Study 30815973 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) only (Group B)
Number of subjects: 185
Study 30815973 — intervention group
Group type: COMPARATOR
Intervention: No MPA and no SMBG (Group A)
Number of subjects: 185
Study 28850712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applications every six months
Number of subjects: 275
Study 28850712 — intervention group
Group type: COMPARATOR
Intervention: Placebo applications every six months
Number of subjects: 275
Study 26730446 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release guanfacine hydrochloride (1-6 mg)
Number of subjects: 26
Study 26730446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24691730 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine for 14 days
Number of subjects: 12
Study 24691730 — intervention group
Group type: COMPARATOR
Intervention: No medication (control) for 14 days
Number of subjects: 12
Study 22070196 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision high addition multifocal contact lenses (PM)
Number of subjects: 20
Study 22070196 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 20
Study 22070196 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Number of subjects: 20
Study 20522709 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy regimens consisting of cytosine arabinoside (Ara‐C), daunorubicin (D), and etoposide (E) with PSC‐833 (ADEP)
Number of subjects: 302
Study 20522709 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy regimens consisting of cytosine arabinoside (Ara‐C), daunorubicin (D), and etoposide (E) without PSC‐833 (ADE)
Number of subjects: 302
Study 20522709 — intervention group
Group type: EXPERIMENTAL
Intervention: ADEP (with PSC‐833)
Number of subjects: 302
Study 20522709 — intervention group
Group type: COMPARATOR
Intervention: ADE (without PSC‐833)
Number of subjects: 302
Study 17999333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (50 g day(‐1)) treatment with low-protein diet (LPD) (<40 g day(‐1)) in group A
Number of subjects: 36
Study 17999333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (50 g day(‐1)), iron (ferrous sulphate, 200 mg day(‐1)), and folic acid (5 mg day(‐1)) treatment in group B
Number of subjects: 36
Study 17999333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (50 g day(‐1)) treatment in normal volunteers (group D)
Number of subjects: 36
Study 17999333 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C): CRF patients under LPD and iron and folic acid treatment
Number of subjects: 36
Study 19922878 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 201
Study 19922878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 15178380 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory semantic and morpho-syntactic priming paradigm with German adjectives correctly or incorrectly inflected for gender and semantically associated or not associated with the target noun.
Number of subjects: 0
Study 15178380 — intervention group
Group type: COMPARATOR
Intervention: Auditory semantic and morpho-syntactic priming paradigm with German adjectives.
Number of subjects: 0
Study 11718157 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 every three weeks)
Number of subjects: 477
Study 11718157 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 477
Study 11718157 — intervention group
Group type: COMPARATOR
Intervention: Good palliative care
Number of subjects: 477
Study 11718157 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine or ifosfamide
Number of subjects: 477
Study 9863072 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplement (1 mg orally on the second day of hospitalization)
Number of subjects: 75
Study 9863072 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 75
Study 7887118 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (EDR) 0.5 mg kg‐1 + atropine (ATR) 0.007 mg kg‐1
Number of subjects: 64
Study 7887118 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (NST) 0.04 mg kg‐1 + glycopyrrolate (GLY) 0.008 mg kg‐1
Number of subjects: 64
Study 3394630 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported psychological distress levels
Number of subjects: 125
Study 3394630 — intervention group
Group type: COMPARATOR
Intervention: Known predictors of arrhythmias (including cardiac risk, age, beta-blocker agents)
Number of subjects: 125
Study 31506292 — intervention group
Group type: EXPERIMENTAL
Intervention: Selonsertib (18 mg)
Number of subjects: 333
Study 31506292 — intervention group
Group type: EXPERIMENTAL
Intervention: Selonsertib (2 mg)
Number of subjects: 333
Study 31506292 — intervention group
Group type: EXPERIMENTAL
Intervention: Selonsertib (6 mg)
Number of subjects: 333
Study 31506292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 28834453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical rAd-IFNα/Syn3 (1 × 10^11 vp/mL)
Number of subjects: 43
Study 28834453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical rAd-IFNα/Syn3 (3 × 10^11 vp/mL)
Number of subjects: 43
Study 28834453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical rAd-IFNα/Syn3
Number of subjects: 43
Study 26802597 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate (TPM)
Number of subjects: 100
Study 26802597 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (OLZ)
Number of subjects: 100
Study 26802597 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline thyrotropin profile (TSHAUC)
Number of subjects: 100
Study 25529911 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nursing rounds every 1‐2 hours
Number of subjects: 100
Study 25529911 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 100
Study 22277179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 36
Study 22277179 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretic (CD) therapy
Number of subjects: 36
Study 19535222 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 30
Study 19535222 — intervention group
Group type: COMPARATOR
Intervention: Intrinsic atrioventricular conduction
Number of subjects: 30
Study 17456217 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate (FP) 100 microg daily
Number of subjects: 13
Study 17456217 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate (FP) 400 microg daily
Number of subjects: 13
Study 17456217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13